nach oben

Current Addiction Reports

Erschienen in:

11.09.2024

Improving Sleep to Address Co-Occurring Substance Use Disorder and Chronic Pain: Exploring the Potential of the Orexin (Hypocretin) System as a Clinical Target

verfasst von: Chung Jung Mun, Matthew J. Reid, Sarah Sarandos, Kit K. Elam, Celine Mylx Li, Justin C. Strickland

Erschienen in: Current Addiction Reports | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

The present review investigates the potential of the orexin system as a clinical target for co-morbid substance use disorder (SUD) and chronic pain, focusing on improving sleep disturbances, an important shared risk factor. We synthesize current evidence from both human and animal studies and proposes viable future research directions to address existing knowledge gaps.

Recent findings

Sleep disturbances significantly contribute to both SUD and chronic pain. The orexin system plays a vital role in sleep–wake regulation, and emerging evidence suggests the orexin system's unique involvement in drug-related reward functioning and pain modulation. Hence, the orexin system presents a unique opportunity to address the complex interplay between SUD, chronic pain, and sleep disturbances. Orexin receptor antagonists, particularly Dual Orexin Receptor Antagonists (DORAs) that are FDA-approved for treating insomnia, show considerable promise as novel treatments for both SUD and chronic pain.

Summary

The current review highlights orexin system’s complex role in SUD and chronic pain. While preliminary evidence for DORAs in treating SUD and chronic pain is promising, critical gaps remain in limited human clinical trials, long-term effects, safety, abuse liability, and understanding of the orexin system’s underlying mechanisms in both problematic substance use and pain. Future studies should explore appropriate dosing regimens, the potential of different types of orexin antagonists, including Selective Orexin Receptor Antagonists (SORAs) and combined SORA and DORA therapies, and consider individual differences (e.g., sex differences) to realize their full therapeutic potential for co-morbid SUD and chronic pain.

Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, et al. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. Morb Mortal Wkly Rep. 2018;67:1001–6. https://doi.org/10.15585/mmwr.mm6736a2.CrossRef

Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13:715–24. https://doi.org/10.1016/j.jpain.2012.03.009.CrossRefPubMed

U.S. Department of Health and Human Services [HHS]. SAMHSA Announces National Survey on Drug Use and Health (NSDUH): Results Detailing Mental Illness and Substance Use Levels in 2021. 2023 Available from: https://www.hhs.gov/about/news/2023/01/04/samhsa-announces-national-survey-drug-use-health-results-detailing-mental-illness-substance-use-levels-2021.html. Accessed 25 Jun 2024.

Center for Diease Control and Prevention. Drug Overdose Deaths. 2023. Available from: https://www.cdc.gov/drugoverdose/deaths/index.html. Accessed 25 Jun 2024.

Ditre JW, Zale EL, LaRowe LR. A reciprocal model of pain and substance use: Transdiagnostic considerations, clinical implications, and future directions. Annu Rev Clin Psychol. 2019;15:503–28. https://doi.org/10.1146/annurev-clinpsy-050718-095440.CrossRefPubMed

Danagoulian S, King A, Mangan K, Tarchick J, Dolcourt B. Fewer opioids but more benzodiazepines? Prescription trends by specialty in response to the implementation of Michigan’s opioid laws. Pain Med. 2022;23:403–13. https://doi.org/10.1093/pm/pnab270.CrossRefPubMed

Zvolensky MJ, Cougle JR, Bonn-Miller MO, Norberg MM, Johnson K, Kosiba J, et al. Chronic pain and marijuana use among a nationally representative sample of adults. Am J Addict. 2011;20:538–42. https://doi.org/10.1111/j.1521-0391.2011.00176.x.CrossRefPubMed

Orhurhu VJ, Pittelkow TP, Hooten WM. Prevalence of smoking in adults with chronic pain. Tob Induc Dis. 2015;13:1–6. https://doi.org/10.1186/s12971-015-0030-0.CrossRef

Smiley-McDonald HM, Moore KN, Heller DC, Ropero-Miller JD, McIntire GL, Wallace FN. Patterns of marijuana use in a 6-month pain management sample in the United States. Subst Abus Res Treat. 2017;11:1178221817724783. https://doi.org/10.1177/1178221817724783.CrossRef

10.

Hser Y-I, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26–30. https://doi.org/10.1016/j.jsat.2017.03.006.CrossRefPubMedPubMedCentral

11.

Latif ZH, Skjærvø I, Solli KK, Tanum L. Chronic pain among patients with an opioid use disorder. Am J Addict. 2021;30:366–75. https://doi.org/10.1111/ajad.13153.CrossRefPubMed

12.

Maleki N, Tahaney K, Thompson BL, Oscar-Berman M. At the intersection of alcohol use disorder and chronic pain. Neuropsychology. 2019;33:795–807. https://doi.org/10.1037/neu0000558.CrossRefPubMedPubMedCentral

13.

Sun Y, Laksono I, Selvanathan J, Saripella A, Nagappa M, Pham C, et al. Prevalence of sleep disturbances in patients with chronic non-cancer pain: A systematic review and meta-analysis. Sleep Med Rev. 2021;101467. https://doi.org/10.1016/j.smrv.2021.101467.

14.

Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain. 2013;14:1539–52. https://doi.org/10.1016/j.jpain.2013.08.007.CrossRefPubMedPubMedCentral

15.

Kundermann B, Krieg J-C, Schreiber W, Lautenbacher S. The effects of sleep deprivation on pain. Pain Res Manag. 2004;9:25–32. https://doi.org/10.1155/2004/949187.CrossRefPubMed

16.

Lautenbacher S, Kundermann B, Krieg J-C. Sleep deprivation and pain perception. Sleep Med Rev. 2006;10:357–69. https://doi.org/10.1016/j.smrv.2005.08.001.CrossRefPubMed

17.

Shibata S, Tahara Y, Hirao A. The adjustment and manipulation of biological rhythms by light, nutrition, and abused drugs. Adv Drug Deliv Rev. 2010;62:918–27. https://doi.org/10.1016/j.addr.2010.06.003.CrossRefPubMed

18.

Conroy DA, Arnedt JT. Sleep and substance use disorders: an update. Curr Psychiatry Rep. 2014;16:1–9. https://doi.org/10.1007/s11920-014-0487-3.CrossRef

19.

Marchant EG, Mistlberger RE. Morphine phase-shifts circadian rhythms in mice: role of behavioural activation. NeuroReport. 1995;7:209–2012.PubMed

20.

Byku M, Gannon RL. Opioid induced non-photic phase shifts of hamster circadian activity rhythms. Brain Res. 2000;873:189–96. https://doi.org/10.1016/s0006-8993(00)02304-0.CrossRefPubMed

21.

Meijer JH, Ruijs ACJ, Albus H, van de Geest B, Duindam H, Zwinderman AH, et al. Fentanyl, a μ-opioid receptor agonist, phase shifts the hamster circadian pacemaker. Brain Res. 2000;868:135–40. https://doi.org/10.1016/s0006-8993(00)02317-9.CrossRefPubMed

22.

Vansteensel MJ, Magnone MC, Van Oosterhout F, Baeriswyl S, Albrecht U, Albus H, et al. The opioid fentanyl affects light input, electrical activity and Per gene expression in the hamster suprachiasmatic nuclei. Eur J Neurosci. 2005;21:2958–66. https://doi.org/10.1111/j.1460-9568.2005.04131.x.CrossRefPubMed

23.

Roehrs T, Sibai M, Roth T. Sleep and alertness disturbance and substance use disorders: A bi-directional relation. Pharmacol Biochem Behav. 2021;203:173153. https://doi.org/10.1016/j.pbb.2021.173153.CrossRefPubMedPubMedCentral

24.

Huhn AS, Finan PH. Sleep disturbance as a therapeutic target to improve opioid use disorder treatment. Exp Clin Psychopharmacol. 2022;30:1024–35. https://doi.org/10.1037/pha0000477.CrossRefPubMed

25.

Koob GF, Colrain IM. Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework. Neuropsychopharmacology. 2020;45:141–65. https://doi.org/10.1038/s41386-019-0446-0.CrossRefPubMed

26.

Greenwald MK, Moses TEH, Roehrs TA. At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities. Transl Res. 2021;234:58–73. https://doi.org/10.1016/j.trsl.2021.03.006.CrossRefPubMedPubMedCentral

27.

Bonifazi A, Del Bello F, Giorgioni G, Piergentili A, Saab E, Botticelli L, et al. Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders. Med Res Rev. 2023;43:1607–67. https://doi.org/10.1002/med.21959.CrossRefPubMed

28.

Ahmadi-Soleimani SM, Mianbandi V, Azizi H, Azhdari-Zarmehri H, Ghaemi-Jandabi M, Abbasi-Mazar A, et al. Coregulation of sleep-pain physiological interplay by orexin system: An unprecedented review. Behav Brain Res. 2020;391:112650. https://doi.org/10.1016/j.bbr.2020.112650.CrossRefPubMed

29.

Sakurai T. Orexins and orexin receptors: implication in feeding behavior. Regul Pept. 1999;85:25–30. https://doi.org/10.1016/s0167-0115(99)00076-2.CrossRefPubMed

30.

De Lecea L, Kilduff TS, Peyron C, Gao X-B, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci. 1998;95:322–7. https://doi.org/10.1073/pnas.95.1.322.CrossRefPubMedPubMedCentral

31.

Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Physiol. 2013;304:C2-32. https://doi.org/10.1152/ajpcell.00227.2012.CrossRef

32.

Zhu Y, Miwa Y, Yamanaka A, Yada T, Shibahara M, Abe Y, et al. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and-insensitive G-proteins. J Pharmacol Sci. 2003;92:259–66. https://doi.org/10.1254/jphs.92.259.CrossRefPubMed

33.

Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243–66. https://doi.org/10.1146/annurev-pharmtox-010510-100528.CrossRefPubMedPubMedCentral

34.

Sakurai T, Saito YC, Yanagisawa M. Interaction between Orexin Neurons and Monoaminergic Systems. In: Steiner MA, Yanagisawa M, Clozel M, editors. Orexin Syst Basic Sci Role Sleep Pathol. S.Karger AG; 2021. p. 11–21. https://doi.org/10.1159/000514955.

35.

Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci. 2001;21:1656–62. https://doi.org/10.1523/JNEUROSCI.21-05-01656.2001.CrossRefPubMedPubMedCentral

36.

Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol. 2008;29:70–87. https://doi.org/10.1016/j.yfrne.2007.08.001.CrossRefPubMed

37.

Espana RA, Baldo BA, Kelley AE, Berridge CW. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience. 2001;106:699–715. https://doi.org/10.1016/s0306-4522(01)00319-0.CrossRefPubMed

38.

Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep–wake cycle of rats. Eur J Neurosci. 2000;12:726–30. https://doi.org/10.1046/j.1460-9568.2000.00919.x.CrossRefPubMed

39.

Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469–74. https://doi.org/10.1016/s0896-6273(00)00058-1.CrossRefPubMedPubMedCentral

40.

Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59:1553–62. https://doi.org/10.1001/archneur.59.10.1553.CrossRefPubMed

41.

Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365–76. https://doi.org/10.1016/s0092-8674(00)81965-0.CrossRefPubMed

42.

Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437–51. https://doi.org/10.1016/s0092-8674(00)81973-x.CrossRefPubMed

43.

Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8:171–81. https://doi.org/10.1038/nrn2092.CrossRefPubMed

44.

Hondo M, Nagai K, Ohno K, Kisanuki Y, Willie JT, Watanabe T, et al. Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. Acta Physiol. 2010;198:287–94. https://doi.org/10.1111/j.1748-1716.2009.02032.x.CrossRef

45.

Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003;38:715–30. https://doi.org/10.1016/s0896-6273(03)00330-1.CrossRefPubMed

46.

Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol. 2014;171:283–93. https://doi.org/10.1111/bph.12261.CrossRefPubMed

47.

Yang LPH. Suvorexant: first global approval. Drugs. 2014;74:1817–22. https://doi.org/10.1007/s40265-014-0294-5.CrossRefPubMed

48.

Scott LJ. Lemborexant: first approval. Drugs. 2020;80:425–32. https://doi.org/10.1007/s40265-020-01276-1.CrossRefPubMed

49.

Markham A. Daridorexant: first approval. Drugs. 2022;82:601–7. https://doi.org/10.1007/s40265-022-01699-y.CrossRefPubMedPubMedCentral

50.

De Crescenzo F, D’Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400:170–84. https://doi.org/10.1016/S0140-6736(22)00878-9.CrossRefPubMed

51.

Moline M, Asakura S, Beuckman C, Landry I, Setnik B, Ashworth J, et al. The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology. 2023;240:699–711. https://doi.org/10.1007/s00213-023-06320-y.CrossRefPubMedPubMedCentral

52.

Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36:259–67. https://doi.org/10.5665/sleep.2386.CrossRefPubMedPubMedCentral

53.

Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep. 2014;37:1609–19. https://doi.org/10.5665/sleep.4068.CrossRefPubMedPubMedCentral

54.

Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, et al. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis. Sleep Med Rev. 2022;61:101573. https://doi.org/10.1016/j.smrv.2021.101573.CrossRefPubMed

55.

McElroy H, O’Leary B, Adena M, Campbell R, Monfared AAT, Meier G. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis. J Manag care Spec Pharm. 2021;27:1296–308. https://doi.org/10.18553/jmcp.2021.21011.CrossRefPubMed

56.

Preskorn SH. Comparative Pharmacology of the 3 marketed dual orexin antagonists—daridorexant, lemborexant, and suvorexant: Part 1: Pharmacokinetic profiles. J Psychiatr Pract. 2022;28:478–80. https://doi.org/10.1097/PRA.0000000000000672.CrossRefPubMed

57.

Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol. 2020;87:347–56. https://doi.org/10.1002/ana.25680.CrossRefPubMed

58.

Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature. 2005;437:556–9. https://doi.org/10.1038/nature04071.CrossRefPubMed

59.

Dayas CV, McGranahan TM, Martin-Fardon R, Weiss F. Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse. Biol Psychiatry. 2008;63:152–7. https://doi.org/10.1016/j.biopsych.2007.02.002.CrossRefPubMed

60.

Harris GC, Wimmer M, Randall-Thompson JF, Aston-Jones G. Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. Behav Brain Res. 2007;183:43–51. https://doi.org/10.1016/j.bbr.2007.05.025.CrossRefPubMedPubMedCentral

61.

Jupp B, Krstew E, Dezsi G, Lawrence A. Discrete cue-conditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin1 receptors. Br J Pharmacol. 2011;162:880–9. https://doi.org/10.1111/j.1476-5381.2010.01088.x.CrossRefPubMedPubMedCentral

62.

Martin-Fardon R, Cauvi G, Kerr TM, Weiss F. Differential role of hypothalamic orexin/hypocretin neurons in reward seeking motivated by cocaine versus palatable food. Addict Biol. 2018;23:6–15. https://doi.org/10.1111/adb.12441.CrossRefPubMed

63.

Barson JR, Leibowitz SF. Orexin/hypocretin system: role in food and drug overconsumption. Int Rev Neurobiol. 2017;136:199–237. https://doi.org/10.1016/bs.irn.2017.06.006.CrossRefPubMedPubMedCentral

64.

Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci. 2005;102:19168–73. https://doi.org/10.1073/pnas.0507480102.CrossRefPubMedPubMedCentral

65.

Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron. 2006;49:589–601. https://doi.org/10.1016/j.neuron.2006.01.016.CrossRefPubMed

66.

España RA, Melchior JR, Roberts DCS, Jones SR. Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. Psychopharmacology. 2011;214:415–26. https://doi.org/10.1007/s00213-010-2048-8.CrossRefPubMed

67.

Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci. 2003;23:7–11. https://doi.org/10.1523/JNEUROSCI.23-01-00007.2003.CrossRefPubMedPubMedCentral

68.

España RA, Oleson EB, Locke JL, Brookshire BR, Roberts DCS, Jones SR. The hypocretin–orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci. 2010;31:336–48. https://doi.org/10.1111/j.1460-9568.2009.07065.x.CrossRefPubMed

69.

Brodnik ZD, Bernstein DL, Prince CD, España RA. Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep. Behav Brain Res. 2015;291:377–84. https://doi.org/10.1016/j.bbr.2015.05.051.CrossRefPubMedPubMedCentral

70.

Shaw JK, Ferris MJ, Locke JL, Brodnik ZD, Jones SR, España RA. Hypocretin/orexin knock-out mice display disrupted behavioral and dopamine responses to cocaine. Addict Biol. 2017;22:1695–705. https://doi.org/10.1111/adb.12432.CrossRefPubMed

71.

Nishizawa D, Kasai S, Hasegawa J, Sato N, Yamada H, Tanioka F, et al. Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence in genome-wide and subsequent association studies. Mol Brain. 2015;8:1–17. https://doi.org/10.1186/s13041-015-0142-x.CrossRef

72.

Chen W-Y, Kao C-F, Chen P-Y, Lin S-K, Huang M-C. Orexin-A level elevation in recently abstinent male methamphetamine abusers. Psychiatry Res. 2016;239:9–11. https://doi.org/10.1016/j.psychres.2016.02.059.CrossRefPubMed

73.

Tsai M-C, Huang T-L. Orexin A in men with heroin use disorder undergoing methadone maintenance treatment. Psychiatry Res. 2018;264:412–5. https://doi.org/10.1016/j.psychres.2018.04.010.CrossRefPubMed

74.

Sadat-Shirazi M-S, Soltani H, Nikpour N, Haghshenas M, Khalifeh S, Mokri A, et al. Alteration of orexin-A and PKCα in the postmortem brain of pure-opioid and multi-drug abusers. Neuropeptides. 2020;83:102074. https://doi.org/10.1016/j.npep.2020.102074.CrossRefPubMed

75.

Lee W-C, Chen P-Y, Kao C-F, Huang M-C. Differences in serum orexin-A levels between the acute and subacute withdrawal phases in individuals who use methamphetamine. Exp Clin Psychopharmacol. 2021;29:573–9. https://doi.org/10.1037/pha0000395.CrossRefPubMed

76.

Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LHT, Guan X-M. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998;438:71–5. https://doi.org/10.1016/s0014-5793(98)01266-6.CrossRefPubMed

77.

Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6–25. https://doi.org/10.1002/cne.1190.CrossRefPubMed

78.

Matzeu A, Martin-Fardon R. Targeting the orexin system for prescription opioid use disorder. Brain Sci. 2020;10:226. https://doi.org/10.3390/brainsci10040226.CrossRefPubMedPubMedCentral

79.

Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res. 2020;1731:145922. https://doi.org/10.1016/j.brainres.2018.08.025.CrossRefPubMed

80.

James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology. 2020;45:717–9. https://doi.org/10.1038/s41386-020-0619-x.CrossRefPubMedPubMedCentral

81.

Han Y, Yuan K, Zheng Y, Lu L. Orexin receptor antagonists as emerging treatments for psychiatric disorders. Neurosci Bull. 2020;36:432–48. https://doi.org/10.1007/s12264-019-00447-9.CrossRefPubMed

82.

Matzeu A, Martin-Fardon R. Understanding the role of orexin neuropeptides in drug addiction: Preclinical studies and translational value. Front Behav Neurosci. 2022;15:787595. https://doi.org/10.3389/fnbeh.2021.787595.CrossRefPubMedPubMedCentral

83.

Martin-Fardon R, Weiss F. Blockade of hypocretin receptor-1 preferentially prevents cocaine seeking: comparison with natural reward seeking. NeuroReport. 2014;25:485. https://doi.org/10.1097/WNR.0000000000000120.CrossRefPubMedPubMedCentral

84.

Martin-Fardon R, Weiss F. N-(2-methyl-6-benzoxazolyl)-N′-1, 5-naphthyridin-4-yl urea (SB 334867), a hypocretin receptor-1 antagonist, preferentially prevents ethanol seeking: comparison with natural reward seeking. Addict Biol. 2014;19:233–6. https://doi.org/10.1111/j.1369-1600.2012.00480.x.CrossRefPubMed

85.

Bentzley BS, Aston-Jones G. Orexin-1 receptor signaling increases motivation for cocaine-associated cues. Eur J Neurosci. 2015;41:1149–56. https://doi.org/10.1111/ejn.12866.CrossRefPubMedPubMedCentral

86.

Fragale JE, James MH, Aston-Jones G. Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system. Addict Biol. 2021;26:e12946. https://doi.org/10.1111/adb.12946.CrossRefPubMed

87.

James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G. Increased number and activity of a lateral subpopulation of hypothalamic orexin/hypocretin neurons underlies the expression of an addicted state in rats. Biol Psychiatry. 2019;85:925–35. https://doi.org/10.1016/j.biopsych.2018.07.022.CrossRefPubMed

88.

James MH, Bowrey HE, Stopper CM, Aston-Jones G. Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin-1 receptor antagonist in rats. Eur J Neurosci. 2019;50:2602–12. https://doi.org/10.1111/ejn.14166.CrossRefPubMed

89.

Porter-Stransky KA, Bentzley BS, Aston-Jones G. Individual differences in orexin-I receptor modulation of motivation for the opioid remifentanil. Addict Biol. 2017;22:303–17. https://doi.org/10.1111/adb.12323.CrossRefPubMed

90.

Bernstein DL, Badve PS, Barson JR, Bass CE, España RA. Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine. Addict Biol. 2018;23:1032–45. https://doi.org/10.1111/adb.12553.CrossRefPubMed

91.

Hollander JA, Pham D, Fowler CD, Kenny PJ. Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence. Front Behav Neurosci. 2012;6:47. https://doi.org/10.3389/fnbeh.2012.00047.CrossRefPubMedPubMedCentral

92.

Schmeichel BE, Barbier E, Misra KK, Contet C, Schlosburg JE, Grigoriadis D, et al. Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats. Neuropsychopharmacol. 2015;40:1123–9. https://doi.org/10.1038/npp.2014.293.CrossRef

93.

Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non-opioid neurotransmitter systems that contribute to the opioid withdrawal syndrome: a review of preclinical and human evidence. J Pharmacol Exp Ther. 2019;371:422–52. https://doi.org/10.1124/jpet.119.258004.CrossRefPubMedPubMedCentral

94.

Roehrs TA, Roth T. Sleep disturbance in substance use disorders. Psychiatr Clin. 2015;38:793–803. https://doi.org/10.1016/j.psc.2015.07.008.CrossRef

95.

Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL, et al. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Sci Transl Med. 2022;14:eabn8238. https://doi.org/10.1126/scitranslmed.abn8238.CrossRefPubMed

96.

Suchting R, Yoon JH, San Miguel GG, Green CE, Weaver MF, Vincent JN, et al. Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder. Brain Res. 2020;1731:146359. https://doi.org/10.1016/j.brainres.2019.146359.CrossRefPubMed

97.

Stoops WW, Strickland JC, Hatton KW, Hays LR, Rayapati AO, Lile JA, et al. Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans. Pharmacol Biochem Behav. 2022;220:173466. https://doi.org/10.1016/j.pbb.2022.173466.CrossRefPubMedPubMedCentral

98.

Strickland JC, Hatton KW, Hays LR, Rayapati AO, Lile JA, Rush CR, et al. Use of drug purchase tasks in medications development research: orexin system regulation of cocaine and drug demand. Behav Pharmacol. 2023;34:275–86. https://doi.org/10.1097/FBP.0000000000000731.CrossRefPubMedPubMedCentral

99.

Kang X, Tang H, Liu Y, Yuan Y, Wang M. Research progress on the mechanism of orexin in pain regulation in different brain regions. Open Life Sci. 2021;16:46–52. https://doi.org/10.1515/biol-2021-0001.CrossRefPubMedPubMedCentral

100.

Azhdari-Zarmehri H, Semnanian S, Fathollahi Y. Orexin-A microinjection into the rostral ventromedial medulla causes antinociception on formalin test. Pharmacol Biochem Behav. 2014;122:286–90. https://doi.org/10.1016/j.pbb.2014.03.017.CrossRefPubMed

101.

Kargar HM, Azizi H, Mirnajafi-Zadeh J, Reza MA, Semnanian S. Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. Brain Res. 2015;1624:424–32. https://doi.org/10.1016/j.brainres.2015.07.050.CrossRef

102.

Inutsuka A, Yamashita A, Chowdhury S, Nakai J, Ohkura M, Taguchi T, et al. The integrative role of orexin/hypocretin neurons in nociceptive perception and analgesic regulation. Sci Rep. 2016;6:29480. https://doi.org/10.1038/srep29480.CrossRefPubMedPubMedCentral

103.

Youn D, Jun J, Kim TW, Park K. Spinal orexin A attenuates opioid-induced mechanical hypersensitivity in the rat. Korean J Pain. 2022;35:433–9. https://doi.org/10.3344/kjp.2022.35.4.433.CrossRefPubMedPubMedCentral

104.

Rezaee L, Karimi-Haghighi S, Fazli-Tabaei S, Haghparast A. Effects of intrathecal administration of orexin-1 receptor antagonist on antinociceptive responses induced by chemical stimulation of lateral hypothalamus in an animal model of tonic nociception. Neuropeptides. 2018;69:19–25. https://doi.org/10.1016/j.npep.2018.03.002.CrossRefPubMed

105.

Wardach J, Wagner M, Jeong Y, Holden JE. Lateral hypothalamic stimulation reduces hyperalgesia through spinally descending orexin-A neurons in neuropathic pain. West J Nurs Res. 2016;38:292–307. https://doi.org/10.1177/0193945915610083.CrossRefPubMed

106.

Matsuura W, Nakamoto K, Tokuyama S. Involvement of descending pain control system regulated by orexin receptor signaling in the induction of central post-stroke pain in mice. Eur J Pharmacol. 2020;874:173029. https://doi.org/10.1016/j.ejphar.2020.173029.CrossRefPubMed

107.

Haghparast A, Matini T, Rezaee L, Rahban M, Tehranchi A, Haghparast A. Involvement of orexinergic system within the nucleus accumbens in pain modulatory role of the lateral hypothalamus in orofacial pain model. Neurochem Res. 2020;45:851–9. https://doi.org/10.1007/s11064-020-02957-9.CrossRefPubMed

108.

Askari K, Oryan S, Eidi A, Zaringhalam J, Haghparast A. Modulatory role of the orexin system in stress-induced analgesia: Involvement of the ventral tegmental area. Eur J Pain. 2021;25:2266–77. https://doi.org/10.1002/ejp.1840.CrossRefPubMed

109.

Azhdari-Zarmehri H, Esmaeili M-H, Sofiabadi M, Haghdoost-Yazdi H. Orexin receptor type-1 antagonist SB-334867 decreases morphine-induced antinociceptive effect in formalin test. Pharmacol Biochem Behav. 2013;112:64–70. https://doi.org/10.1016/j.pbb.2013.09.018.CrossRefPubMed

110.

Soleimani SMA, Azizi H, Mirnajafi-Zadeh J, Semnanian S. Orexin type 1 receptor antagonism in rat locus coeruleus prevents the analgesic effect of intra-LC met-enkephalin microinjection. Pharmacol Biochem Behav. 2015;136:102–6. https://doi.org/10.1016/j.pbb.2015.07.010.CrossRef

111.

Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain. 2004;109:367–78. https://doi.org/10.1016/j.pain.2004.02.005.CrossRefPubMed

112.

Sarchielli P, Rainero I, Coppola F, Rossi C, Mancini ML, Pinessi L, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28:714–22. https://doi.org/10.1111/j.1468-2982.2008.01566.x.CrossRefPubMed

113.

Chavan P, Chikahisa S, Shiuchi T, Shimizu N, Dalanon J, Okura K, et al. Dual orexin receptor antagonist drug suvorexant can help in amelioration of predictable chronic mild stress-induced hyperalgesia. Brain Res Bull. 2022;188:39–46. https://doi.org/10.1016/j.brainresbull.2022.07.011.CrossRefPubMed

114.

Hoffmann J, Supronsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, et al. Evidence for orexinergic mechanisms in migraine. Neurobiol Dis. 2015;74:137–43. https://doi.org/10.1016/j.nbd.2014.10.022.CrossRefPubMed

115.

Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia. 2015;35:379–88. https://doi.org/10.1177/0333102414544979.CrossRefPubMed

116.

Roehrs T, Withrow D, Koshorek G, Verkler J, Bazan L, Roth T. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo. J Clin Sleep Med. 2020;16:415–21. https://doi.org/10.5664/jcsm.8220.CrossRefPubMedPubMedCentral

117.

Finan PH, Smith MT. The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism. Sleep Med Rev. 2013;17:173–83. https://doi.org/10.1016/j.smrv.2012.03.003.CrossRefPubMed

118.

Motomura Y, Katsunuma R, Ayabe N, Oba K, Terasawa Y, Kitamura S, et al. Decreased activity in the reward network of chronic insomnia patients. Sci Rep. 2021;11:3600. https://doi.org/10.1038/s41598-020-79989-2.CrossRefPubMedPubMedCentral

119.

Smith MT, Edwards RR, McCann UD, Haythornthwaite JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep. 2007;30:494–505. https://doi.org/10.1093/sleep/30.4.494.CrossRefPubMed

120.

Ito H, Tsuneki H, Sasaoka T, Toyooka N, Matsuo M, Yamazaki M. Suvorexant and mirtazapine improve chronic pain-related changes in parameters of sleep and voluntary physical performance in mice with sciatic nerve ligation. PLoS ONE. 2022;17:e0264386. https://doi.org/10.1371/journal.pone.0264386.CrossRefPubMedPubMedCentral

121.

Reid MJ, Dunn KE, Abraham L, Ellis J, Hunt CA, Gamaldo CE, et al. Suvorexant alters dynamics of the sleep-EEG power spectrum and depressive symptom trajectories during inpatient opioid withdrawal. Sleep. 2024;47:zsae025. https://doi.org/10.1093/sleep/zsae025.CrossRefPubMed

122.

Hale L, Troxel W, Buysse DJ. Sleep health: an opportunity for public health to address health equity. Annu Rev Public Health. 2020;41:81–99. https://doi.org/10.1146/annurev-publhealth-040119-094412.CrossRefPubMedPubMedCentral

123.

Idorsia Urges DEA to De-schedule DORA Class of Insomnia Medications. 2023. Available from: https://sleepreviewmag.com/sleep-disorders/insomnia/idorsia-urges-dea-de-schedule-dora-class-insomnia-medications/ Accesssed 25 Jun 2024.

124.

Grafe LA, Bhatnagar S. The contribution of orexins to sex differences in the stress response. Brain Res. 2020;1731:145893. https://doi.org/10.1016/j.brainres.2018.07.026.CrossRefPubMed

125.

McHugh RK, Votaw VR, Sugarman DE, Greenfield SF. Sex and gender differences in substance use disorders. Clin Psychol Rev. 2018;66:12–23. https://doi.org/10.1016/j.cpr.2017.10.012.CrossRefPubMed

126.

Sorge RE, Totsch SK. Sex differences in pain. J Neurosci Res. 2017;95:1271–81. https://doi.org/10.1002/jnr.23841.CrossRefPubMed

Titel: Improving Sleep to Address Co-Occurring Substance Use Disorder and Chronic Pain: Exploring the Potential of the Orexin (Hypocretin) System as a Clinical Target
verfasst von: Chung Jung Mun
Matthew J. Reid
Sarah Sarandos
Kit K. Elam
Celine Mylx Li
Justin C. Strickland
Publikationsdatum: 11.09.2024
Verlag: Springer International Publishing
Erschienen in: Current Addiction Reports / Ausgabe 6/2024
Elektronische ISSN: 2196-2952
DOI: https://doi.org/10.1007/s40429-024-00598-4

Fear of Missing Out, Gaming Disorder and Internet Gaming Disorder: Systematic Review

LGBT-THC: A Systematic Review of Psychosocial Mechanisms Linking Minority Stressors and Cannabis Use among Sexual and Gender Minoritized Individuals

Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review

Sleep Characteristics Among Children with a Parental History of Alcohol Use Disorder

Open Access

Parsing the Prospective Links from Externalizing and Internalizing Symptoms to Substance Use: A Systematic Review and Meta-Analysis

Correction to: Managing Pain with Opioids in the Setting of Substance Use Disorder

Correction

Neu im Fachgebiet Psychiatrie

Einer von sieben Frauen macht die Menopause sehr zu schaffen

15.01.2025
Menopause
Nachrichten

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Depressive Senioren fahren besonders riskant

14.01.2025
Altersdepression
Nachrichten

Beim Autofahren machen ältere Depressive häufiger eine Vollbremsung, gehen öfter zu schnell in Kurven und halten sich seltener an Tempolimits als Senioren ohne Depression. Offenbar scheint eine Depression eine riskante Fahrweise im Alter zu verstärken.

Verhaltenstherapie plus Stimulanz reduziert Binge Eating

14.01.2025
Binge-Eating-Störung
Nachrichten

Die Kombination von kognitiver Verhaltenstherapie plus Lisdexamfetamin bringt Personen mit Binge-Eating-Störung deutlich häufiger in Remission als die jeweiligen Einzeltherapien. Zudem nimmt das Gewicht der Betroffenen spürbar ab.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Improving Sleep to Address Co-Occurring Substance Use Disorder and Chronic Pain: Exploring the Potential of the Orexin (Hypocretin) System as a Clinical Target

Abstract

Purpose of review

Recent findings

Summary

Weitere Artikel der Ausgabe 6/2024

Fear of Missing Out, Gaming Disorder and Internet Gaming Disorder: Systematic Review

LGBT-THC: A Systematic Review of Psychosocial Mechanisms Linking Minority Stressors and Cannabis Use among Sexual and Gender Minoritized Individuals

Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review

Sleep Characteristics Among Children with a Parental History of Alcohol Use Disorder

Parsing the Prospective Links from Externalizing and Internalizing Symptoms to Substance Use: A Systematic Review and Meta-Analysis

Correction to: Managing Pain with Opioids in the Setting of Substance Use Disorder

Neu im Fachgebiet Psychiatrie

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Depressive Senioren fahren besonders riskant

Verhaltenstherapie plus Stimulanz reduziert Binge Eating

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Update Psychiatrie

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten